Elemento
Russian-developed COVID-19 Vaccine Interim Trial Reports 92% Success Rate
Título (Dublin Core)
Russian-developed COVID-19 Vaccine Interim Trial Reports 92% Success Rate
Description (Dublin Core)
Following initial findings of Pfizer's vaccine being effective in preventing COVID-19 infection in more than 90% of people, Russia says its vaccine has 92% efficacy according to preliminary findings in stage three of the clinical trials. The trial results are based on 20 confirmed COVID-19 cases.
Date (Dublin Core)
November 11, 2020
Creator (Dublin Core)
Polina Ivanova 7 MIN READ
Contributor (Dublin Core)
Tina Chang
Event Identifier (Dublin Core)
HSE
Partner (Dublin Core)
Arizona State University
Tipo (Dublin Core)
screenshot
Link (Bibliographic Ontology)
Controlled Vocabulary (Dublin Core)
English
Health & Wellness
English
Public Health & Hospitals
Curator's Tags (Omeka Classic)
vaccine
Russia
medical trial
Sputnik V
placebo
Contributor's Tags (a true folksonomy) (Friend of a Friend)
Russia
COVID-19
vaccine
Collection (Dublin Core)
English
Vaccine Stories
Linked Data (Dublin Core)
Date Submitted (Dublin Core)
11/12/2020
Date Modified (Dublin Core)
11/13/2020
1/31/2021
03/15/2021
Date Created (Dublin Core)
11/11/2020
This item was submitted on November 12, 2020 by Tina Chang using the form “Share Your Story” on the site “A Journal of the Plague Year”: https://covid-19archive.org/s/archive
Click here to view the collected data.